2020: Incubated in Berlin, Germany
August 2021
April 2021: Establishment of ROCROCK in Shenzhen
August 2021
August 2021: ROCROCK in Shenzhen awarded Third Prize in Ping Shan District Innovation and Entrepreneurship Competition's Biomass Specialty Competition
October 2021
October 2021: ROCROCK in Shenzhen recognized as Outstanding Project in National Disruptive Technology Innovation Competition
October 2021
October 2021: ROCROCK in Shenzhen honored with Excellent Enterprise Award in the 13th China Shenzhen Innovation and Entrepreneurship Competition's Biopharmaceutical Industry Final
December 2021
December 2021: ROCROCK in Shenzhen ranked among the Top 50 Innovative Biotech Companies in the Greater Bay Area
March 2022
March 2022: ROCROCK in Shenzhen recognized as a Technology-Oriented Small and Medium-Sized Enterprise
August 2022
August 2022: First Place in the Dongwu Science and Technology Innovation and Entrepreneurship Competition
October 2022
October 2022: Angel Round Financing of Tens of Millions
November 2022
November 2022: Establishment of ROC ROCK in Suzhou
November 2022
November 2022: ROC ROCK in Suzhou recognized as Leading Technological Talent in Suzhou Industrial Park
November 2022
November 2022: Collaboration Agreement between ROC ROCK and PUHENG TECHNOLOGY in Suzhou
December 2022
December 2022: Collaboration with Juechuang Bio to Advance IIT
January 2023
January 2023: Inauguration of ROC ROCK Berlin Research and Development Center
April 2023
April 2023: Completion of ROC ROCK Suzhou Base
May 2023
May 2023: CAR-M Solid Tumor Therapy Project Enters IIT Phase
May 2023
May 2023: Deep Collaboration Agreement with Karolinska Institute
June 2023
June 2023: Expert Appointment Agreement with Shandong Port Medical and Health Management Group
September 2023
A strategic clinical collaboration for CAR-M targeted therapy in autoimmune diseases was initiated. Rock Roc Biotechnology, Nanjing Drum Tower Hospital
December 2023
Deeply international cooperation with the Armenian Institute of Molecular Biology
December 2023
The third generation of CAR-M clinical subjects was successfully enrolled
December 2023
Selected in the national "list of" technical research projects
January 2024
Successfully completed the administration and evaluation of the third generation CAR-M in clinical subjects
January 2024
Completed tens of millions of yuan Pre-A round of financing
March 2024
IND declaration strategic cooperation with PORTON Biology




lliangjing@rocrockbio.com (Shenzhen)